Skip to main content
SpringerLink
Log in

Topiramat, Perampanel und Brivaracetam im Status epilepticus

Wie anzuwenden und was können wir erwarten?

Topiramate, perampanel and brivaracetam in status epilepticus

How should they be used and what effect can be expected?

  • Leitthema
  • Published:
Zeitschrift für Epileptologie Aims and scope Submit manuscript

Zusammenfassung

Im Status epilepticus werden bei Versagen der Erstlinientherapie mit Benzodiazepinen und intravenösen Antikonvulsiva wie Phenytoin, Valproat oder Levetiracetam weitere Substanzen eingesetzt. In diesem Beitrag werden die zum aktuellen Zeitpunkt vorliegenden Daten und publizierten Erfahrungen zum Einsatz von 2 ausschließlich enteral (Topiramat, Perampanel) und einem enteral und parenteral verfügbaren Antikonvulsivum (Brivaracetam) zusammengefasst, die pharmakologisch und klinisch relevanten Daten im Einsatz dieser Substanzen im SE dargestellt und Empfehlungen zum praktischen klinischen Einsatz gegeben.

Abstract

Once benzodiazepines and intravenous anticonvulsants, such as phenytoin, valproate or levetiracetam fail in the first line treatment of status epilepticus, further anticonvulsants are used. This article describes the currently available data and publications on the use of two exclusively enteral anticonvulsants (topiramate and perampanel) and an enteral and parenteral anticonvulsant (brivaracetam) in status epilepticus. The pharmacological and clinical data on the use of these substances in status epilepticus are presented and recommendations are given for use in daily clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Sutter R, De Marchis GM, Semmlack S, Fuhr P, Ruegg S, Marsch S et al (2017) Anesthetics and outcome in status epilepticus: a matched two-center cohort study. CNS Drugs 31(1):65–74

    Article  CAS  Google Scholar 

  2. Sutter R, Marsch S, Fuhr P, Kaplan PW, Ruegg S (2014) Anesthetic drugs in status epilepticus: risk or rescue? A 6‑year cohort study. Neurology 82(8):656–664

    Article  CAS  Google Scholar 

  3. Alvarez V, Lee JW, Westover MB, Drislane FW, Novy J, Faouzi M et al (2016) Therapeutic coma for status epilepticus: differing practices in a prospective multicenter study. Neurology 87(16):1650–1659

    Article  CAS  Google Scholar 

  4. Beuchat I, Novy J, Rossetti AO (2018) Newer antiepileptic drugs for status epilepticus in adults: What’s the evidence? CNS Drugs 32(3):259–267

    Article  CAS  Google Scholar 

  5. Shorvon S, Ferlisi M (2011) The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 134(Pt 10):2802–2818

    Article  Google Scholar 

  6. Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F (2017) Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany. Epilepsia 58(9):1533–1541

    Article  Google Scholar 

  7. Rosenfeld WE (1997) Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 19(6):1294–1308

    Article  CAS  Google Scholar 

  8. Clark AM, Kriel RL, Leppik IE, Marino SE, Mishra U, Brundage RC et al (2013) Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia 54(6):1099–1105

    Article  CAS  Google Scholar 

  9. Clark AM, Kriel RL, Leppik IE, White JR, Henry TR, Brundage RC et al (2013) Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. Epilepsia 54(6):1106–1111

    Article  CAS  Google Scholar 

  10. Reuber M, Evans J, Bamford JM (2002) Topiramate in drug-resistant complex partial status epilepticus. Eur J Neurol 9(1):111–112

    Article  CAS  Google Scholar 

  11. Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ (2003) The use of topiramate in refractory status epilepticus. Neurology 60(2):332–334

    Article  CAS  Google Scholar 

  12. Kortland LM, Alfter A, Bahr O, Carl B, Dodel R, Freiman TM et al (2016) Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia 57(12):2056–2066

    Article  Google Scholar 

  13. Kellinghaus C, Rossetti AO, Trinka E, Lang N, Unterberger I, Ruegg S et al (2018) SENSE registry for status epilepticus. Epilepsia 59: in press

    Article  CAS  Google Scholar 

  14. Perry MS, Holt PJ, Sladky JT (2006) Topiramate loading for refractory status epilepticus in children. Epilepsia 47(6):1070–1071

    Article  Google Scholar 

  15. Brigo F, Trinka E (2017) Randomized controlled trials in status epilepticus: size matters. Epilepsia 58(5):915

    Article  Google Scholar 

  16. Brigo F, Bragazzi NL, Igwe SC, Nardone R, Trinka E (2017) Topiramate in the treatment of generalized convulsive status epilepticus in adults: a systematic review with individual patient data analysis. Drugs 77(1):67–74

    Article  CAS  Google Scholar 

  17. Synowiec AS, Yandora KA, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM (2012) The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res 98(2–3):232–237

    Article  CAS  Google Scholar 

  18. Strzelczyk A, Willems LM, Willig S, Rosenow F, Bauer S (2015) Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol 8(6):733–740

    Article  CAS  Google Scholar 

  19. Niquet J, Baldwin R, Suchomelova L, Lumley L, Naylor D, Eavey R et al (2016) Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment. Ann N Y Acad Sci 1378(1):166–173

    Article  CAS  Google Scholar 

  20. Naylor DE, Liu H, Wasterlain CG (2005) Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25(34):7724–7733

    Article  CAS  Google Scholar 

  21. Wasterlain CG, Liu H, Naylor DE, Thompson KW, Suchomelova L, Niquet J et al (2009) Molecular basis of self-sustaining seizures and pharmacoresistance during status epilepticus: the receptor trafficking hypothesis revisited. Epilepsia 50(Suppl 12):16–18

    Article  Google Scholar 

  22. Di Bonaventura C, Labate A, Maschio M, Meletti S, Russo E (2017) AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives. Expert Opin Pharmacother 18(16):1751–1764

    Article  Google Scholar 

  23. Patsalos PN (2015) The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia 56(1):12–27

    Article  CAS  Google Scholar 

  24. French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A et al (2012) Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79(6):589–596

    Article  Google Scholar 

  25. French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D et al (2013) Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 54(1):117–125

    Article  CAS  Google Scholar 

  26. Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J et al (2012) Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78(18):1408–1415

    Article  CAS  Google Scholar 

  27. Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clement JF et al (2014) Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia 55(7):1058–1068

    Article  CAS  Google Scholar 

  28. Hanada T, Ido K, Kosasa T (2014) Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect 2(5):e63

    Article  Google Scholar 

  29. Rösche J, Kampf C, Benecke R (2013) Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus. Acta Neurol Belg. https://doi.org/10.1007/s13760-013-0225-3

    Article  PubMed  Google Scholar 

  30. Santamarina E, Sueiras M, Lidon RM, Guzman L, Baneras J, Gonzalez M et al (2015) Use of perampanel in one case of super-refractory hypoxic myoclonic status: case report. Epilepsy Behav Case Rep 4:56–59

    Article  Google Scholar 

  31. Redecker J, Wittstock M, Benecke R, Rosche J (2015) Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav 45:176–179

    Article  Google Scholar 

  32. Rohracher A, Hofler J, Kalss G, Leitinger M, Kuchukhidze G, Deak I et al (2015) Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav 49:354–358

    Article  CAS  Google Scholar 

  33. Mirandola L, Giovannini G, Monti G, Meletti S (2017) High-dose perampanel in super refractory status epilepticus: effects on EEG and vital parameters. 32nd International Epilepsy Congress 2017. Abstract A‑905-0017-01108

  34. Alsherbini KM, Jones G, Goyal N (2017) The use and efficary of Perampanel in refractory status epilepticus. AES Annual Meeting 2017. (Abst. 1.194)

    Google Scholar 

  35. Beretta S, Padovano G, Stabile A, Coppo A, Bogliun G, Avalli L, Ferrarese C (2017) Efficacy and safety of perampanel oral loading in post-anoxic super-refractory status epilepticus: a case series. Epilepsia 58(Suppl. 5):S5–S199 (p0444)

    Google Scholar 

  36. Kjaer TW, Atkins M, Friedrich J, Gyllenborg J (2017) The efficacy of perampanel in refractory status epilepticus. Epilepsia 58(Suppl. 5):S5–S199 (p0550)

    Google Scholar 

  37. Rohracher A, Höfler J, Kalss G, Leitinger M, Kuchukhidze G, Neuray C, Dobesberger J, Trinka E (2016) Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. AES Annual Meeting. (Abst. 1.289)

    Google Scholar 

  38. Sueiras MS, Santamarina E, Lidon RM, Guzman L, Baneras J, Gonzalez M, Toledo M, Salas-Puig X (2015) Use of perampanel (per) in two cases of super-refractory hypoxic myoclonic status. Epilepsia 56(Suppl. 1):3–263 (p1067)

    Google Scholar 

  39. Rohracher A, Kalss G, Neuray C, Hofler J, Dobesberger J, Kuchukhidze G et al (2018) Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: a single-center audit of 30 patients. Epilepsia. https://doi.org/10.1111/epi.14494

    Article  PubMed  Google Scholar 

  40. Strzelczyk A, Klein KM, Willems LM, Rosenow F, Bauer S (2016) Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol 9(5):637–645

    Article  CAS  Google Scholar 

  41. Zahnert F, Krause K, Immisch I, Habermehl L, Gorny I, Chmielewska I et al (2018) Brivaracetam in the treatment of patients with epilepsy-first clinical experiences. Front Neurol 9:38

    Article  Google Scholar 

  42. Steinig I, von Podewils F, Moddel G, Bauer S, Klein KM, Paule E et al (2017) Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia 58(7):1208–1216

    Article  CAS  Google Scholar 

  43. Steinhoff BJ, Bacher M, Bucurenciu I, Hillenbrand B, Intravooth T, Kornmeier R et al (2017) Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy – a monocenter survey. Seizure 48:11–14

    Article  Google Scholar 

  44. Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D et al (2016) Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 57(2):201–209

    Article  CAS  Google Scholar 

  45. Sargentini-Maier ML, Espie P, Coquette A, Stockis A (2008) Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 36(1):36–45

    Article  CAS  Google Scholar 

  46. Stockis A, Sargentini-Maier ML, Horsmans Y (2013) Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol 53(6):633–641

    Article  CAS  Google Scholar 

  47. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2010) Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 92(2–3):89–124

    Article  Google Scholar 

  48. Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A (2008) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 66(1):71–75

    Article  CAS  Google Scholar 

  49. Mumoli L, Palleria C, Gasparini S, Citraro R, Labate A, Ferlazzo E et al (2015) Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther 9:5719–5725

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Sargentini-Maier ML, Sokalski A, Boulanger P, Jacobs T, Stockis A (2012) Brivaracetam disposition in renal impairment. J Clin Pharmacol 52(12):1927–1933

    Article  CAS  Google Scholar 

  51. Stockis A, Chanteux H, Rosa M, Rolan P (2015) Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res 113:19–27

    Article  CAS  Google Scholar 

  52. von Rosenstiel P (2007) Brivaracetam (UCB 34714). Neurotherapeutics 4(1):84–87

    Article  Google Scholar 

  53. Stockis A, Watanabe S, Scheen AJ (2015) Effect of brivaracetam on CYP3A activity, measured by oral midazolam. J Clin Pharmacol 55(5):543–548

    Article  CAS  Google Scholar 

  54. Strzelczyk A, Steinig I, Willems LM, Reif PS, Senft C, Voss M et al (2017) Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav 70(Pt A):177–181

    Article  Google Scholar 

  55. Kalss G, Rohracher A, Leitinger M, Pilz G, Novak HF, Neuray C et al (2018) Intravenous brivaracetam in status epilepticus: a retrospective single-center study. Epilepsia. https://doi.org/10.1111/epi.14486

    Article  PubMed  Google Scholar 

  56. Strzelczyk A, Kay L, Bauer S, Immisch I, Klein KM, Knake S et al (2018) Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 59(8):1549–1556

    Article  CAS  Google Scholar 

  57. Kay L, Reif PS, Belke M, Bauer S, Frund D, Knake S et al (2015) Intranasal midazolam during presurgical epilepsy monitoring is well tolerated, delays seizure recurrence, and protects from generalized tonic-clonic seizures. Epilepsia 56(9):1408–1414

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Neurologie, Christian-Doppler-Klinik, Paracelsus Medizinische Privatuniversität Salzburg, Salzburg, Österreich

    Alexandra Rohracher

  2. Klinik für Neurologie, Epilepsiezentrum Münster-Osnabrück, Klinikum Osnabrück, Am Finkenhügel 1, 49076, Osnabrück, Deutschland

    Christoph Kellinghaus

  3. Epilepsiezentrum Frankfurt Rhein-Main und Klinik für Neurologie, Goethe-Universität, Frankfurt am Main, Deutschland

    Adam Strzelczyk

  4. Epilepsiezentrum Hessen und Klinik für Neurologie, Philipps-Universität, Marburg, Deutschland

    Adam Strzelczyk

Authors
  1. Alexandra Rohracher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Kellinghaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adam Strzelczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph Kellinghaus.

Ethics declarations

Interessenkonflikt

A. Rohracher erhielt Reiseunterstützung und Vortragshonorare von Eisai. C. Kellinghaus erhielt Beratungs- und Referentenhonorare von NrSign Inc, Eisai und UCB Pharma. A. Strzelczyk erhielt Beratungs‑, Referentenhonorare und/oder Unterstützung für Forschungsvorhaben von Desitin Arzneimittel, Eisai, LivaNova, Sage Therapeutics, UCB Pharma und Zogenix.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rohracher, A., Kellinghaus, C. & Strzelczyk, A. Topiramat, Perampanel und Brivaracetam im Status epilepticus. Z. Epileptol. 31, 256–261 (2018). https://doi.org/10.1007/s10309-018-0206-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10309-018-0206-x

Schlüsselwörter

Keywords

Search

Navigation